Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for JW Shinyak Corporation (067290:KRX), powered by AI.
JW Shinyak Corporation is currently trading at ₩1,775. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for JW Shinyak Corporation on Alpha Lenz.
JW Shinyak Corporation's P/E ratio is 4.9.
“JW Shinyak Corporation trades at a P/E of 4.9 (undervalued) with strong ROE of 46.3%.”
Ask for details →JW Shinyak Corporation is a pharmaceutical company specializing in the development, manufacture, and distribution of innovative healthcare products. Primarily focused on the creation of prescription drugs, over-the-counter medicines, and therapeutic treatments, JW Shinyak plays a vital role in the biotech and healthcare industries. It addresses a range of therapeutic areas, including cardiovascular diseases, oncology, and central nervous system disorders. As part of the broader pharmaceutical landscape, JW Shinyak Corporation contributes significantly to advancing medical research and providing access to quality healthcare solutions. Established in South Korea, the company operates in both domestic and international markets, offering its products to healthcare providers, pharmacies, and hospitals worldwide. Beyond product development, JW Shinyak is committed to enhancing patient outcomes through continuous research and strategic collaborations.
“JW Shinyak Corporation trades at a P/E of 4.9 (undervalued) with strong ROE of 46.3%.”
Ask for details →JW Shinyak Corporation (ticker: 067290) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $76.5B.
The current price is ₩1,775 with a P/E ratio of 4.89x and P/B of 1.88x.
ROE is 46.30% and operating margin is 9.20%. Annual revenue is $81.0B.